Inflammation is characterized by migration of neutrophils through the endothelium, and the chemokine interleukin-8 (IL-8) appears t o be involved. We asked whether adherence of cells bearing a membrane-form of interleukin 1 (IL-l) induces IL-8 secretion from human umbilical vein endothelial cells (HUVEC) and fibroblasts. Human peripheral blood mononuclear cells (PBMC) were stimulated with endotoxin for 12 hours and then fixed for 4 hours with paraformaldehyde. When these cells were added t o HUVEC or fibroblasts, IL-8 production was induced. This stimulation by fixed PBMC was attributed t o IL-l, because pretreatment of HUVEC or fibroblasts with IL-l receptor antagonist (IL-1Ra) reduced the induction by 95% and 8096, respectively, P < .005. Using anti-IL-la monoclonal antibodies, reduction was complete, whereas anti-IL-Ip had no effect. IL-la was shown on the surface of monocytes by fluorescence-activated cell sorter HE TWO FORMS of interleukin-l (IL-l), IL-la and XL-10, are initially synthesized as precursor molecules of 31 k D , and are processed to smaller molecules, particularly mature forms of 17.5 kD.'-3 IL-l,B is the predominant form found in physiologic fluids of patients with various infectious, inflammatory, or hematologic diseases, whereas IL-la is mainly associated with cells. In 1985, Kurt-Jones et a1 described an IL-1 activity on the membrane of stimulated murine macrophages, using fixation with paraformaldehyde (PFA).4 Since then, numerous studies have described this form of IL-1 on a variety of cells following stimulation with agents that increase the synthesis of IL-1.5 The so called membrane-bound XL-l was shown to be the 3 1 kD precursor form of IL-la.',' Indeed, the precursor form of IL-la, contrary to that of IL-lp, binds to the type X IL-l receptor and is biologically active.' The concept of membrane IL-l a remains controversial because both forms of IL-I, in their precursor or mature forms, lack a hydrophobic sequence and, therefore, are not expected to be associated with lipid bilayers3 However, the anchoring of IL-I to the membrane could be due to a lectin-like mechanism.' In addition, other The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1994 by The American Society of Hematology. 0006-4971/94/8412-0005$3.00/0 4242 (FACS) analysis. Blockade of IL-l receptors on PBMC did not affect the activity of membrane-associated IL-la, indicating that IL-l is not anchored to the membrane through its receptors. However, PBMC treated with D-mannose before fixation resulted in a loss of activity; this loss of activity was associated with release of IL-la, not IL-la, into the supernatant. Thus, anchoring of IL-la to the membrane may be via a lectin or mannose receptor-like interaction. Blockade of membrane IL-la required a 30-fold and fivefold excess of IL1Ra compared with the amount required t o block soluble ILIp and IL-la, respectively. We conclude that the fixed PBMC IL-8 inducing activity is almost entirely caused by IL-l, that this represents IL-la bound t o a surface lectin or mannose receptor on the monocyte, and that it functions in inflammation via juxtacrine interactions.
Inflammation is characterized by migration of neutrophils through the endothelium, and the chemokine interleukin-8 (IL-8) appears t o be involved. We asked whether adherence of cells bearing a membrane-form of interleukin 1 (IL-l) induces IL-8 secretion from human umbilical vein endothelial cells (HUVEC) and fibroblasts. Human peripheral blood mononuclear cells (PBMC) were stimulated with endotoxin for 12 hours and then fixed for 4 hours with paraformaldehyde. When these cells were added t o HUVEC or fibroblasts, IL-8 production was induced. This stimulation by fixed PBMC was attributed t o IL-l, because pretreatment of HUVEC or fibroblasts with IL-l receptor antagonist (IL-1Ra) reduced the induction by 95% and 8096, respectively, P < .005. Using anti-IL-la monoclonal antibodies, reduction was complete, whereas anti-IL-Ip had no effect. IL-la was shown on the surface of monocytes by fluorescence-activated cell sorter HE TWO FORMS of interleukin-l (IL-l), IL-la and XL-10, are initially synthesized as precursor molecules of 31 k D , and are processed to smaller molecules, particularly mature forms of 17.5 kD.'-3 IL-l,B is the predominant form found in physiologic fluids of patients with various infectious, inflammatory, or hematologic diseases, whereas IL-la is mainly associated with cells. In 1985, Kurt-Jones et a1 described an IL-1 activity on the membrane of stimulated murine macrophages, using fixation with paraformaldehyde (PFA). 4 Since then, numerous studies have described this form of IL-1 on a variety of cells following stimulation with agents that increase the synthesis of IL-1.5 The so called membrane-bound XL-l was shown to be the 3 1 kD precursor form of IL-la.',' Indeed, the precursor form of IL-la, contrary to that of IL-lp, binds to the type X IL-l receptor and is biologically active.' The concept of membrane IL-l a remains controversial because both forms of IL-I, in their precursor or mature forms, lack a hydrophobic sequence and, therefore, are not expected to be associated with lipid bilayers3 However, the anchoring of IL-I to the membrane could be due to a lectin-like mechanism.' In addition, other (FACS) analysis. Blockade of IL-l receptors on PBMC did not affect the activity of membrane-associated IL-la, indicating that IL-l is not anchored to the membrane through its receptors. However, PBMC treated with D-mannose before fixation resulted in a loss of activity; this loss of activity was associated with release of IL-la, not IL-la, into the supernatant. Thus, anchoring of IL-la to the membrane may be via a lectin or mannose receptor-like interaction. Blockade of membrane IL-la required a 30-fold and fivefold excess of IL1Ra compared with the amount required t o block soluble ILIp and IL-la, respectively. We conclude that the fixed PBMC IL-8 inducing activity is almost entirely caused by IL-l, that this represents IL-la bound t o a surface lectin or mannose receptor on the monocyte, and that it functions in inflammation via juxtacrine interactions. cytokines, such as tumor necrosis factor a (TNFa) or transforming growth factor a, have been shown to be biologically active in membrane-associated forms.'"' These membraneassociated forms of cytokines may be important in cell to cell, juxtacrine, interactions, and at locally mediated events,l~'.l?. 13 Among the critical events involved in inflammation and infection are adhesion of the polymorphonuclear cells (PMN) to the endothelium and their migration through the vascular The latter has been shown to be partially mediated by IL-8, a chemotactic cytokine secreted by monocytes, fibroblasts, and endothelial cells in response to stimulation with IL-l, TNF or endotoxin lipopolysaccharide (LPS)."~*' Because migration of the PMN through the endothelium is primarily a local event involving cell to cell interactions, we asked whether membrane-associated XL-l could induce L 8 secretion by endothelial cells and fibroblasts in vitro. For that purpose, we used a long fixation procedure in PFA that prevents release of IL-l in the supernatants." Subsequently, we asked what mechanisms are involved in the anchoring of 1L-l to the membrane. Cell cultures. Human umbilical vein endothelial cells (HUVEC) were prepared as previously described?' and used between passages 2 and 4. Cells were grown until confluent in 24-well plates coated with 1% gelatin. Before the experiments, cells were incubated in complete culture medium, consisting of ultrafiltrated RPMIY 100 UlmL penicillin G , 100 pg/mL streptomycin, 1% L-glutamine, and 10% heat-inactivated FCS. Neonatal human dermal fibroblasts were grown in RPMI 1640, supplemented with 10% Serum Plus, IO mmoll L L-glutamine, 100 UlmL penicillin G, and 100 pg/mL streptomycin. The fibroblasts were split into 24-well plates, and grown to confluence in the former medium at 1 mL volumes.
MATERIALS AND METHODS

Materials
Stimulation of peripheral blood mononuclear cells. Peripheral blood mononuclear cells (PBMC) were prepared from freshly drawn heparinized blood by centrifugation on a Ficoll-Hypaque gradient. Using a hemocytometer, cells were adjusted to IO6 cellslmL in complete culture medium. PBMC were stimulated with IO nglmL of LPS for 1 hour, at 37"C, 5% CO2, in polypropylene tubes. This was followed by a 14-hour rotation (2.5 rpm/min) at 37°C as previously described.25 As a control, PBMC were incubated at the same conditions, but without LPS stimulation. After the incubation, the cells were washed three times in RPMI.
Fixation of PEMC. After washing, the PBMC pellets were resuspended in freshly prepared 1% PFA in phosphate buffered saline, pH 7.4, at room temperature for 4 hours?' and then washed three times in RPMI. The fixed PBMC were resuspended in complete culture medium, and lo6 cells were added to each well of HUVEC or 2 X IO5 cells to each well of fibroblasts. After 20 hours at 37"C, the supernatants were collected, centrifuged for 10 minutes in a microfuge at 4"C, and stored at -75°C for IL-8 assay.
Treatment with D-mannose. PBMC were stimulated with LPS as described above, and incubated with 0.5 m o L D-mannose or RPMI for I hour at 4°C. Supernatants were separated from cell pellets and stored at -75°C before assaying for IL-la and IL-ID. The pellets were washed three times in RPMI, assessed for viability with trypan blue, and readjusted to 10' cells/mL. The cells were fixed with PFA as described above, and IO6 cellslmL were added to the HUVEC for 20 hours. Supernatants were then removed and IL-8 was measured.
Fluorescence-activated cell sorter (FACS) analysis. Staining was performed as described previously,5 using the following sequence: ( l ) unconjugated anti-IL-la and anti-IL-lo MoAb, or an irrelevant IgGl (20 pg/mL), (2) biotinylated goat antimouse IgG (l/ 50). (3) normal mouse IgG (20 pg/mL) to block residual binding sites for mouse Ig, (4) phycoerythrin-streptavidin complex (11100). Fluorescence was measured on a FACS analyzer (Epics Profile; Coulter, Hialeah, FL).
Radioimmunoassay for IL-la, IL-ID and IL-8. IL-8, IL-la and IL-lp were measured by specific radioimmunoassay (RIA), as previously described.'"'8
Statistical analysis. The data were analyzed for statistical significance by Student's t test. Results are expressed as the mean 2 standard error of the mean of three to six experiments unless otherwise specified.
RESULTS
Paraformaldehyde-jxed PBMC induce IL-8 secretion by
HUVEC. Stimulation of HUVEC with soluble IL-I/? resulted in IL-8 secretion in a dose-dependent fashion (Fig 1,  inset) . A similar dose-response curve was observed using IL-la as a stimulant. At 100 pg/mL, IL-1p-(or IL-la-) induced IL-8 was significant ( P < .01). Fibroblasts secreted higher amounts of K-8 when incubated with either IL-la or 0; using 50 pg/mL IL-l@, 90 to I10 ng/mL of IL-8 were secreted into the supernatant compared with control medium.
LPS-stimulated PBMC, after fixation in PFA for 4 hours, induced IL-8 from HUVEC compared with fixed, but unstimulated PBMC (P = .0001, Fig 1) . The amount of IL-8 produced following stimulation with lo6 fixed PBMC was comparable in magnitude to that induced by 100 pg/mL of either soluble IL-lP or IL-la. The addition of polymyxin B (5 pg/ mL) to the cultures did not reduce the effect (three experiments, data not shown), demonstrating that carry-over of LPS into the HUVEC cultures was not the source of stimulation.
IL-1Ra and anti-IL-la MoAb inhibits the stimulatory effect offixed PBMC. Both HUVEC and fibroblasts secreted IL-8 in response to LPS-stimulated and fixed PBMC. This could be due to IL-1, TNF, or other LPS-stimulated cytokines. However, blockade of IL-l receptors on HUVEC or fibroblasts using 10 pg/mL of IL-1Ra before the addition of fixed PBMC inhibited IL-8 secretion by 95% and 80% ( P = ,0001 and P < .005, respectively). As shown in Fig 2, the presence of anti-IL-la Ab completely inhibited the induction of IL-8 by LPS-stimulated fixed PBMC (P < .002), whereas anti-IL-10 had no effect. The degree of reduction by anti-IL-la was comparable to that of IL-1Ra. Thus, the effect of LPS-stimulated and fixed PBMC was mainly due to IL-l and specifically to a surface form of IL-la.
Stimulated PBMC IL-la activity is not due to passive IL-l leakage. LPS-stimulated PBMC were fixed in PFA for 4 hours, incubated in RPMI for 20 hours at 37"C, and separated from the supernatant by centrifugation. As shown in medium (6.5 ng, not significant). Thus, it is highly unlikely that passive leakage from stimulated and fixed PBMC during the 20 hours of incubation following fixation accounts for the activity of these cells. When IL-la was measured in the 20-hour supernatant, it was below the detection limit of 15 pg/mL. However, as depicted in Fig 3, IL-8 induced by the 20-hour supernatant was nonsignificantly reduced by pretreatment of H W E C with anti-&la MoAb ( P = .08) or IL-1Ra ( P = .09).
Demonstration of IL-la on the membrane of LPS-stimu- lated PBMC by FACS analysis. Expression of IL-la on the membrane of LPS-stimulated PBMC was studied by FACS analysis using anti-IL-la, anti-IL-lp, or an irrelevant IgG of the same isotype (IgGl). The percentage of labeled monocytes was consistently higher using anti-IL-la MoAb than anti-IL-10 MoAb or the irrelevant IgG ( Table 1) . Gating on lymphocytes consistently showed no significant membrane staining using either anti-IL-la or anti-IL-1p MoAb (data not shown).
Effect of D-mannose treatment of PBMC. Fixed LPSstimulated PBMC induced secretion of over 2,000 pg/mL of IL-8 from HUVEC. A significant decrease (90%, P < .W5, plus pretreatment of HUVEC with saturating concentrations of IL-1Ra (Fig 4) . IL-la and IL-10 levels in the supernatants of the D-mannose treated PBMC. Incubation of PBMC with D-mannose displaced the membrane-associated IL-l (Fig 5) . The amounts of L -l p found in the supernatants of the D-mannose-treated cells were not different from those of the nontreated PBMC. In contrast, the amounts of IL-la were significantly higher than in the control supernatants (P < .01).
The amount of IL-la associated with fixed PBMC was approximately 70 pg/106 cells.
Fixation of IL-I is not to IL-I receptors on the surface of PBMC. Recent studies indicate that the type I1 IL-1 receptor on monocytes may act as a decoy for binding IL-l without inducing a signal.29 In such a case, fixation to the type I1 receptor could serve as an anchoring mechanism for ILla before fixation. To prevent IL-1 anchoring on the membrane via IL-1 receptors (either type I or type 11), PBMC from three donors were stimulated with LPS overnight in the presence or absence of saturating concentrations (10 pg/ mL) of L-lRa, then washed, fixed, and added to HUVEC. No significant differences in IL-8 induction were observed between the two treatments (data not shown). To verify that the L-1 receptors were efficiently occupied by these saturating concentrations of IL-lRa, we compared the amount of IL-10 secreted in response to LPS by the IL-1Ra pretreated PBMC. The decrease (42%) was similar to that previously rep~rted."*~'
Thus, the IL-l receptors were functionally occupied by IL-lRa, and this did not affect the binding of membraneassociated IL-l on the surface of the PBMC. Although the blocking IL-1 receptors with saturating concentrations of IL1Ra decreases IL-1p production, the lack of an effect on membrane IL-1 may be due to the relative low amount (2%) of the total amount of IL-la synthesized by PBMC under these conditions. Moreover, as expected, when HUVEC were pretreated with IL-1Ra (10 pg/mL), a significant (83%, P < .01) decreased IL-8 secretion of both preparations of PBMC, ie, L-1Ra pretreated and nonpretreated, was observed (data not shown).
Blockade of soluble and membrane-associated IL-l activities by IL-1Ra. We compared the blocking activity of IL1Ra on soluble and membrane-associated IL-l-induced IL-8 secretion from HUVEC. Stimulated and fixed PBMC (at lo6 cells, corresponding to approximately 70 pg/mL of soluble IL-ID activity), were added to HUVEC pretreated with increasing concentrations of IL-1Ra. In parallel experiments, HUVEC pretreated with IL-1Ra were stimulated with 100 pg/mL of soluble IL-1p. As shown in Fig 6A, 50% inhibition of IL-8 secretion was achieved with IL-1Ra at approximately 1,000 pg/mL for soluble IL-lp, and 30,000 pg/mL for membrane-bound IL-l, indicating a 30-fold difference. When these experiments were performed with soluble IL-la (two experiments), 50% inhibition of the IL-8 secretion was observed with IL-1Ra at 6,000 pg/mL for the soluble form and at 30,000 pg/mL for the membrane-bound IL-1, representing a fivefold difference (Fig 6B) .
HUVEC were stimulated for 20 hours with increasing concentrations of either soluble, mature forms of IL-lP, or IL-la. IL-8 secretion by unstimulated HUVEC was set at 100%. For IL-10 at 25, 50, 100, and 500 pg/mL there was a 175%, 235%, 255%, and 250% increase whereas for ILla stimulation, 127%, l%%, 175%, and 257% increases were measured. These data are means of three wells per IL-1 concentration in one of three representative experiments. Compared with the data shown in Fig 6, the difference between soluble and membrane IL-l activity on HUVEC cannot be accounted for as differences in soluble IL-1 isoforms.
DISCUSSION
In this study, we found that PBMC fixed after LPS-stimulation induced IL-8 secretion by both HUVEC and fibroblasts. This effect was not due to carry-over of LPS from the PBMC cultures because polymyxin B did not reduce IL-8 production.I6.l8 The induction of IL-8 by fixed PBMC on HUVEC or fibroblasts was blocked by the presence of IL-1RA demonstrating that the activity is due to IL-1. Furthermore, using anti-L-la, we observed a complete reduction of this activity, whereas anti-IL-lp MoAb had no inhibitory effect. These results implicate biologically active IL-la as isoform of IL-1 being fixed to the surface of the LPS-stimulated monocyte.
The IL-1 activity of fixed PBMC is due to a membrane associated form of IL-la and not to passive leakage of the cytokine. This conclusion is supported by several observations. First, we used a long fixation procedure in PFA,22 in which we demonstrate no release of biologic activity from these cells even after 20 hours of culture, despite the fact that these cells contain 10 to 15 ng/mL of cytosolic L-la. Second, the supernatant from the 20 hour incubation did not contain detectable IL-la, nor was there a significant reduction using IL-1Ra or anti-IL-la. Third, in the experiments using mannose to prevent lectin binding, there was no IL-8-inducing activity in the fixed cells despite exposure to millimolar concentrations of D-mannose. Therefore, the reports of membrane leakage after short fixation of PBMC in IL-1Ra pg/ml PFA32.33 is ruled out in these experiments. Immunolocalization studies have shown that IL-l@ is exclusively a cytosolic molecule and that L -l a is at least in part associated with the plasma cell membrane.5.6.34-79 In agreement with these reports, we observed IL-la on the surface of stimulated PBMC, using a highly sensitive staining m e t h~d .~ Because IL-1 lacks hydrophobic sequences, the mechanism of its membrane-anchoring is unclear. The reader should be mindful that there is no control for the effect of the fixative on the structure of pro-IL-la. Nevertheless, one possible mechanism could be fixation of IL-I to its own cell surface receptors, particularly to the type I1 receptor on monocyte^.'^ In such a case, it is difficult to explain how receptor-bound IL-1 would be oriented so that its active site is still available to interact with receptor on the target cells. To rule out this possibility, we blocked IL-1 receptors on PBMC with IL-1Ra and did not observe a decrease in the IL-8-inducing activity, suggesting that membrane-associated IL-la is not bound to its own receptor.
Posttranslational modifications of the precursor of IL-la, such as acyl palmytylation,"O partial mannosylation,' or serine phosphorylati~n:~-~~ are likely to be involved in the mechanism of association of IL-la to the membrane. In this study, we found that incubation of the LPS-stimulated PBMC with D-mannose before fixation resulted in a loss of IL-S induction ability. In D-mannose-treated cultures, ILla, but not IL-lp, was found in the supernatants. Although in the present work we did not attempt to study the molecular weight of membrane associated IL-l , these results are similar to several reports showing that membrane-associated IL-I is the biologically active, 3 1 kD precursor form of 1L-10.~'~ In the present experiments, the amounts of IL-la displaced by D-mannose were in the range of 50 to 80 pg/106 cells. This is in accordance with previous reports estimating membraneassociated IL-1 to represent approximately 1% to 2% of total cell-associated I L -h a This relative low amount of membrane associated IL-la also explains the small but consistent increase in surface staining of IL-la in stimulated PBMC, whereas there was no increase in IL-I@ in the same cells.
These findings also demonstrate a specific effect of the sugar and suggest that a lectin-like mechanism is involved in anchoring IL-la on the membrane of human monocytes, as previously described for murine macrophages.' Another possibility could be the involvement of a D-mannose receptor on the surface of r n o n o c y t e~.~~.~ Moreover, expression of these receptors is a characteristic of mature macrophage~:~.~ and membrane-associated IL-la might also be a This type of activity is now termed juxtacrine." For example, membrane associated TNF may exert a cytotoxic activity on a target cell,I3 or induce polyclonal activation of B lymphocytes during human immunodeficiency virus (HIV) infect i~n .~' In inflammation, PAF, which is coexpressed with P selectin on the surface of endothelial cells, activates PMN and favors their adhesion to the vascular wall through a juxtacrine m e~h a n i s m ?~,~~ Functionally, membrane-associated IL-la may be an important cofactor in antigen presentation to lymphocyte^.'^ In addition to soluble IL-10, membrane-associated IL-la on cells adhering to the endothelium may facilitate PMN extravasation via endothelial IL-8 secretion. In animal models of infection or inflammation, considerably larger amounts of IL-1Ra are required to reduce neutrophil tissue infiltration, compared with the amounts of IL-1Ra required to block exogenously injected IL-1.51 This suggests the existence of a hidden compartment of L-1, which could be due to membrane-associated IL-la. In the present studies, a 30-fold excess of IL-IRa was required to block 50% of the IL-8 secretion induced by membrane-associated IL-l, as compared with soluble IL-10. Therefore, based on the amount of ILla displaced by D-mannose treatment, stimulation of HU-VEC with membrane-associated IL-la is more potent than soluble IL-l@. These findings may be attributed to differences in the affinity patterns of IL-la and IL-1p to the endothelium type I IL-1 receptor.' Using soluble IL-la, however, a fivefold excess of IL-1Ra was still necessary to block 50% of the effect of membrane-associated IL-1, suggesting that membrane-associated IL-1 may be more potent than soluble IL-1. Unlike IL-lp, IL-la is usually undetectable in the circulation of patients with endotoxemia or septic s h o~k .~' .~~ However, our findings as well as previous indicate that IL-la has a highly active role in its membrane-associated form, in vitro. We suggest that membrane-associated IL-1 a is important at the tissue level, and could be involved in immunity and inflammation, as well as in cell assembly, differentiation, and growth through juxtacrine interactions.
